Genzyme/Isis: Has ENHANCE Dulled Mipomersen's Prospects?

In early January, Genzyme nabbed one of the highest-value specialist cholesterol-busting drugs around: Phase III mipomersen, from Isis Pharmaceuticals. But given the ENHANCE-triggered questions around the value of ever-lower LDL, it's reasonable to ask whether mipomersen has a somewhat less rosy prospect in the few weeks since the deal was signed.

More from Business Strategy

More from In Vivo